Equities Analysts Issue Forecasts for BRTX FY2029 Earnings

BioRestorative Therapies, Inc. (NASDAQ:BRTX) – Equities researchers at Roth Capital reduced their FY2029 earnings per share estimates for shares of BioRestorative Therapies in a research note issued on Friday, March 28th. Roth Capital analyst J. Aschoff now expects that the company will earn $6.86 per share for the year, down from their prior forecast of $6.93. The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($1.43) per share.

BioRestorative Therapies Stock Down 1.1 %

NASDAQ BRTX opened at $1.81 on Monday. The firm has a 50-day moving average price of $1.97 and a two-hundred day moving average price of $1.73. BioRestorative Therapies has a 12-month low of $1.03 and a 12-month high of $2.55. The company has a market capitalization of $12.53 million, a P/E ratio of -1.18 and a beta of 64.37.

BioRestorative Therapies (NASDAQ:BRTX) last announced its earnings results on Thursday, March 27th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.07. BioRestorative Therapies had a negative net margin of 2,697.08% and a negative return on equity of 98.49%. The company had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $0.48 million.

Institutional Investors Weigh In On BioRestorative Therapies

An institutional investor recently bought a new position in BioRestorative Therapies stock. Citadel Advisors LLC acquired a new stake in BioRestorative Therapies, Inc. (NASDAQ:BRTX) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 21,481 shares of the company’s stock, valued at approximately $31,000. Citadel Advisors LLC owned approximately 0.31% of BioRestorative Therapies at the end of the most recent reporting period. Institutional investors own 69.38% of the company’s stock.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.